{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28PLB%29", "query": { "intervention": "Placebo (PLB)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28PLB%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T05:08:40.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01328444", "title": "An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "GSK 573719 +GW642444 125/25", "type": "DRUG" }, { "name": "GSK573719 + GW642444 62.5/25", "type": "DRUG" }, { "name": "GSK 573719 125", "type": "DRUG" }, { "name": "GSK 573719 62.5", "type": "DRUG" }, { "name": "GW642444 25", "type": "DRUG" }, { "name": "Plb", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 349, "start_date": "2011-03-01", "completion_date": "2012-06-14", "has_results": true, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Albany", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Medford", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328444" }, { "nct_id": "NCT02856854", "title": "A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cocaine Use Disorder" ], "interventions": [ { "name": "EMB-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cocaine IV", "type": "DRUG" }, { "name": "Saline IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Embera NeuroTherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "21 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2016-07", "completion_date": "2017-07-25", "has_results": false, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02856854" }, { "nct_id": "NCT05262270", "title": "Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Use Disorder" ], "interventions": [ { "name": "Extended-Release Naltrexone", "type": "DRUG" }, { "name": "Extended Release Buprenorphine", "type": "DRUG" }, { "name": "Placebo (PLB) Injectable matched to XR-NTX", "type": "DRUG" }, { "name": "Placebo (PLB) Injectable matched to XR-BUP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 427, "start_date": "2023-04-18", "completion_date": "2025-07-21", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262270" }, { "nct_id": "NCT07219420", "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Palmoplantar Pustulosis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2025-11-14", "completion_date": "2029-11-22", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fremont", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Auburn Hills", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219420" }, { "nct_id": "NCT04218240", "title": "Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Withdrawal" ], "interventions": [ { "name": "Pregabalin 200 MG capsules", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Lofexidine 0.18Mg Tab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2020-12-17", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04218240" }, { "nct_id": "NCT01402492", "title": "Cocaine Use Reduction With Buprenorphine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Cocaine Dependence" ], "interventions": [ { "name": "Buprenorphine + Naltrexone", "type": "DRUG" }, { "name": "Placebo + Naltrexone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 302, "start_date": "2011-09", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01402492" }, { "nct_id": "NCT01323660", "title": "An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "GSK573719/GW642444 125/25", "type": "DRUG" }, { "name": "GSK573719/GW642444 62.5/25", "type": "DRUG" }, { "name": "GSK573719 125", "type": "DRUG" }, { "name": "GSK573719 62.5", "type": "DRUG" }, { "name": "GW642444 25", "type": "DRUG" }, { "name": "placebo", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 307, "start_date": "2011-03-16", "completion_date": "2012-07-16", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 18, "location_summary": "Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Brandon", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323660" }, { "nct_id": "NCT04790487", "title": "Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Allergic Rhinitis", "Nasal Congestion" ], "interventions": [ { "name": "CPM", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Larkin Community Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2019-07-30", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 1, "location_summary": "South Miami, Florida", "locations": [ { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04790487" }, { "nct_id": "NCT03078075", "title": "Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Methamphetamine Use Disorder" ], "interventions": [ { "name": "Naltrexone: Vivitrol®", "type": "DRUG" }, { "name": "Placebo (PLB) Injectable", "type": "DRUG" }, { "name": "Bupropion: Wellbutrin XL®", "type": "DRUG" }, { "name": "Placebo (PLB) Oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 403, "start_date": "2017-05-05", "completion_date": "2019-07-25", "has_results": true, "last_update_posted_date": "2021-05-03", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078075" }, { "nct_id": "NCT00095121", "title": "Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "Placebo (PLB)", "type": "DRUG" }, { "name": "Adefovir Dipivoxil (ADV)", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 173, "start_date": "2004-06", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2012-05-22", "last_synced_at": "2026-09-04T05:08:40.481Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095121" } ] }